Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

Increase the proportion of people with sickle cell disease on Medicare who received disease-modifying therapies — BDBS‑02

Status: Baseline only

  
Image
Baseline only

Most Recent Data:
12.4 percent (2016)

Target:
15.9 percent

Desired Direction:
Increase desired

Baseline:
12.4 percent of Medicare beneficiaries aged 18 to 75 years with sickle cell anemia received disease modifying therapies in accordance with the National Heart, Lung, and Blood Institute (NHLBI)'s guidelines in 2016

Increase the proportion of Medicare beneficiaries with sickle cell disease who receive disease modifying therapies

Target-Setting Method
Percentage point improvement

Summary

Sickle cell disease is the most common genetic blood disorder in the United States, and it’s more common in some racial/ethnic groups. It can affect every system in the body and cause severe acute and chronic pain. Evidence suggests that hydroxyurea, a recommended therapy that’s been used to treat sickle cell disease for decades, can help reduce complications.